Thirty years of HDAC inhibitors: 2020 hindsight

Ho, Terence C. S., Chan, Alex H. Y. and Ganesan, A. (2020) Thirty years of HDAC inhibitors: 2020 hindsight. Journal of Medicinal Chemistry, 63 (21). 12460–12484. ISSN 0022-2623

[img] PDF (Accepted_Manuscript) - Accepted Version
Restricted to Repository staff only until 1 July 2021.

Download (924kB) | Request a copy


It is now thirty years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy, while many others are in clinical development for oncology as well as other therapeutic indications. This perspective reviews the biological and medicinal chemistry advances over the last three decades with an emphasis on the design of selective inhibitors that discriminate between the eleven human HDAC isoforms.

Item Type: Article
Faculty \ School: Faculty of Science > School of Pharmacy
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 07 Jul 2020 23:58
Last Modified: 12 Jun 2021 11:29
DOI: 10.1021/acs.jmedchem.0c00830

Actions (login required)

View Item View Item